Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Oncology Biomarker Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Oncology Biomarker Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Oncology Biomarker Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Lung Cancer
    • 1.4.3 Breast Cancer
    • 1.4.4 Colorectal Cancer
    • 1.4.5 Prostate Cancer
    • 1.4.6 Stomach Cancer
    • 1.4.7 Others
  • 1.5 Market by Application
    • 1.5.1 Global Oncology Biomarker Market Share by Application: 2020 VS 2026
    • 1.5.2 Diagnostics
    • 1.5.3 Drug Discovery And Development
    • 1.5.4 Prognostics
    • 1.5.5 Risk Assessment
    • 1.5.6 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Oncology Biomarker Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Oncology Biomarker Industry
      • 1.6.1.1 Oncology Biomarker Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Oncology Biomarker Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Oncology Biomarker Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Oncology Biomarker Market Perspective (2015-2026)
  • 2.2 Oncology Biomarker Growth Trends by Regions
    • 2.2.1 Oncology Biomarker Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Oncology Biomarker Historic Market Share by Regions (2015-2020)
    • 2.2.3 Oncology Biomarker Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Oncology Biomarker Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Oncology Biomarker Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Oncology Biomarker Players by Market Size
    • 3.1.1 Global Top Oncology Biomarker Players by Revenue (2015-2020)
    • 3.1.2 Global Oncology Biomarker Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Oncology Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Oncology Biomarker Market Concentration Ratio
    • 3.2.1 Global Oncology Biomarker Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Oncology Biomarker Revenue in 2019
  • 3.3 Oncology Biomarker Key Players Head office and Area Served
  • 3.4 Key Players Oncology Biomarker Product Solution and Service
  • 3.5 Date of Enter into Oncology Biomarker Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Oncology Biomarker Historic Market Size by Type (2015-2020)
  • 4.2 Global Oncology Biomarker Forecasted Market Size by Type (2021-2026)

5 Oncology Biomarker Breakdown Data by Application (2015-2026)

  • 5.1 Global Oncology Biomarker Market Size by Application (2015-2020)
  • 5.2 Global Oncology Biomarker Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Oncology Biomarker Market Size (2015-2020)
  • 6.2 Oncology Biomarker Key Players in North America (2019-2020)
  • 6.3 North America Oncology Biomarker Market Size by Type (2015-2020)
  • 6.4 North America Oncology Biomarker Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Oncology Biomarker Market Size (2015-2020)
  • 7.2 Oncology Biomarker Key Players in Europe (2019-2020)
  • 7.3 Europe Oncology Biomarker Market Size by Type (2015-2020)
  • 7.4 Europe Oncology Biomarker Market Size by Application (2015-2020)

8 China

  • 8.1 China Oncology Biomarker Market Size (2015-2020)
  • 8.2 Oncology Biomarker Key Players in China (2019-2020)
  • 8.3 China Oncology Biomarker Market Size by Type (2015-2020)
  • 8.4 China Oncology Biomarker Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Oncology Biomarker Market Size (2015-2020)
  • 9.2 Oncology Biomarker Key Players in Japan (2019-2020)
  • 9.3 Japan Oncology Biomarker Market Size by Type (2015-2020)
  • 9.4 Japan Oncology Biomarker Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Oncology Biomarker Market Size (2015-2020)
  • 10.2 Oncology Biomarker Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Oncology Biomarker Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Oncology Biomarker Market Size by Application (2015-2020)

11 India

  • 11.1 India Oncology Biomarker Market Size (2015-2020)
  • 11.2 Oncology Biomarker Key Players in India (2019-2020)
  • 11.3 India Oncology Biomarker Market Size by Type (2015-2020)
  • 11.4 India Oncology Biomarker Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Oncology Biomarker Market Size (2015-2020)
  • 12.2 Oncology Biomarker Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Oncology Biomarker Market Size by Type (2015-2020)
  • 12.4 Central & South America Oncology Biomarker Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Abbott Laboratories
    • 13.1.1 Abbott Laboratories Company Details
    • 13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
    • 13.1.3 Abbott Laboratories Oncology Biomarker Introduction
    • 13.1.4 Abbott Laboratories Revenue in Oncology Biomarker Business (2015-2020))
    • 13.1.5 Abbott Laboratories Recent Development
  • 13.2 Bristol-Myers Squibb
    • 13.2.1 Bristol-Myers Squibb Company Details
    • 13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
    • 13.2.3 Bristol-Myers Squibb Oncology Biomarker Introduction
    • 13.2.4 Bristol-Myers Squibb Revenue in Oncology Biomarker Business (2015-2020)
    • 13.2.5 Bristol-Myers Squibb Recent Development
  • 13.3 Eli Lilly and Company
    • 13.3.1 Eli Lilly and Company Company Details
    • 13.3.2 Eli Lilly and Company Business Overview and Its Total Revenue
    • 13.3.3 Eli Lilly and Company Oncology Biomarker Introduction
    • 13.3.4 Eli Lilly and Company Revenue in Oncology Biomarker Business (2015-2020)
    • 13.3.5 Eli Lilly and Company Recent Development
  • 13.4 F.Hoffmann-La Roche Ltd.
    • 13.4.1 F.Hoffmann-La Roche Ltd. Company Details
    • 13.4.2 F.Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue
    • 13.4.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Introduction
    • 13.4.4 F.Hoffmann-La Roche Ltd. Revenue in Oncology Biomarker Business (2015-2020)
    • 13.4.5 F.Hoffmann-La Roche Ltd. Recent Development
  • 13.5 Genomic Health
    • 13.5.1 Genomic Health Company Details
    • 13.5.2 Genomic Health Business Overview and Its Total Revenue
    • 13.5.3 Genomic Health Oncology Biomarker Introduction
    • 13.5.4 Genomic Health Revenue in Oncology Biomarker Business (2015-2020)
    • 13.5.5 Genomic Health Recent Development
  • 13.6 GlaxoSmithKline plc
    • 13.6.1 GlaxoSmithKline plc Company Details
    • 13.6.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
    • 13.6.3 GlaxoSmithKline plc Oncology Biomarker Introduction
    • 13.6.4 GlaxoSmithKline plc Revenue in Oncology Biomarker Business (2015-2020)
    • 13.6.5 GlaxoSmithKline plc Recent Development
  • 13.7 Novartis AG
    • 13.7.1 Novartis AG Company Details
    • 13.7.2 Novartis AG Business Overview and Its Total Revenue
    • 13.7.3 Novartis AG Oncology Biomarker Introduction
    • 13.7.4 Novartis AG Revenue in Oncology Biomarker Business (2015-2020)
    • 13.7.5 Novartis AG Recent Development
  • 13.8 Merck & Co.
    • 13.8.1 Merck & Co. Company Details
    • 13.8.2 Merck & Co. Business Overview and Its Total Revenue
    • 13.8.3 Merck & Co. Oncology Biomarker Introduction
    • 13.8.4 Merck & Co. Revenue in Oncology Biomarker Business (2015-2020)
    • 13.8.5 Merck & Co. Recent Development
  • 13.9 Pfizer
    • 13.9.1 Pfizer Company Details
    • 13.9.2 Pfizer Business Overview and Its Total Revenue
    • 13.9.3 Pfizer Oncology Biomarker Introduction
    • 13.9.4 Pfizer Revenue in Oncology Biomarker Business (2015-2020)
    • 13.9.5 Pfizer Recent Development
  • 13.10 Qiagen N.V.
    • 13.10.1 Qiagen N.V. Company Details
    • 13.10.2 Qiagen N.V. Business Overview and Its Total Revenue
    • 13.10.3 Qiagen N.V. Oncology Biomarker Introduction
    • 13.10.4 Qiagen N.V. Revenue in Oncology Biomarker Business (2015-2020)
    • 13.10.5 Qiagen N.V. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Oncology Biomarker status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncology Biomarker development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Abbott Laboratories
    Bristol-Myers Squibb
    Eli Lilly and Company
    F.Hoffmann-La Roche Ltd.
    Genomic Health
    GlaxoSmithKline plc
    Novartis AG
    Merck & Co.
    Pfizer
    Qiagen N.V.

    Market segment by Type, the product can be split into
    Lung Cancer
    Breast Cancer
    Colorectal Cancer
    Prostate Cancer
    Stomach Cancer
    Others
    Market segment by Application, split into
    Diagnostics
    Drug Discovery And Development
    Prognostics
    Risk Assessment
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Oncology Biomarker status, future forecast, growth opportunity, key market and key players.
    To present the Oncology Biomarker development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Oncology Biomarker are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now